NCT02737722View on ClinicalTrials.gov

Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

February 28, 2018

Conditions
Diabetic Foot Infections
Interventions
DRUG

Bisphosphocin Nu-3

DRUG

Placebo

Trial Locations (3)

34677

Journey Research, Inc., Oldsmar

37067

Clinical Research Solutions, Franklin

94115

Center for Clinical Research, Inc., San Francisco

Sponsors
All Listed Sponsors
lead

Lakewood-Amedex Inc

INDUSTRY

NCT02737722 - Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus | Biotech Hunter | Biotech Hunter